|
Synonyms: Cyramza® | IMC-1121B
ramucirumab is an approved drug (FDA & EMA (2014))
Compound class:
Antibody
Comment: Ramucirumab is an anti-VEGF2 receptor (KDR) monoclonal antibody that is used in oncology.
Peptide sequences and structural information for ramucirumab are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. (2002)
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer, 97 (3): 393-9. [PMID:11774295] |
|
2. Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z. (2003)
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem, 278 (44): 43496-507. [PMID:12917408] |
|
3. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY et al.. (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 20 (2): 282-296. [PMID:30665869] |
